Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jan;26(1):36-47.
doi: 10.2337/diacare.26.1.36.

Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program

William H Hernan  1 , Michael Brandle, Ping Zhang, David F Williamson, Margaret J Matulik, Robert E Ratner, John M Lachin, Michael M Engelgau; Diabetes Prevention Program Research Group
Affiliations
Clinical Trial

Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program

William H Hernan et al. Diabetes Care. 2003 Jan.

Abstract

Objective: To describe the costs of the Diabetes Prevention Program (DPP) interventions to prevent or delay type 2 diabetes.

Research design and methods: We describe the direct medical costs, direct nonmedical costs, and indirect costs of the placebo, metformin, and intensive lifestyle interventions over the 3-year study period of the DPP. Resource use and cost are summarized from the perspective of a large health system and society. Research costs are excluded.

Results: The direct medical cost of laboratory tests to identify one subject with impaired glucose tolerance (IGT) was $139. Over 3 years, the direct medical costs of the interventions were $79 per participant in the placebo group, $2,542 in the metformin group, and $2,780 in the lifestyle group. The direct medical costs of care outside the DPP were $272 less per participant in the metformin group and $432 less in the lifestyle group compared with the placebo group. Direct nonmedical costs were $9 less per participant in the metformin group and $1,445 greater in the lifestyle group compared with the placebo group. Indirect costs were $230 greater per participant in the metformin group and $174 less in the lifestyle group compared with the placebo group. From the perspective of a health system, the cost of the metformin intervention relative to the placebo intervention was $2,191 per participant and the cost of the lifestyle intervention was $2,269 per participant over 3 years. From the perspective of society, the cost of the metformin intervention relative to the placebo intervention was $2,412 per participant and the cost of the lifestyle intervention was $3,540 per participant over 3 years.

Conclusions: The metformin and lifestyle interventions are associated with modest incremental costs compared with the placebo intervention. The evaluation of costs relative to health benefits will determine the value of these interventions to health systems and society.

PubMed Disclaimer

Comment in

References

    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. - PMC - PubMed
    1. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
    1. Consumer price index and medical consumer price index [online], year. Available from http://www.economagic.com/blscu.htm Accessed 27 July 2001
    1. Rubin RR, Fujmoto WY, Marrero DG, Brenneman T, Charleston JB, Eddstein SL, Fisher EB, Jordan R, Knowler WC, Lichterman LC, Prince M, Rowe PM. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials. 2002;23:157–171. - PubMed
    1. Lifestyle Manuals of Operation. Available from http://www.bsc.gwu.edu/dpp/manuals.htmlydoc Accessed 18 November 2002

Publication types

MeSH terms